These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 8610026)

  • 21. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy.
    Mazzaro C; Franzin F; Tulissi P; Pussini E; Crovatto M; Carniello GS; Efremov DG; Burrone O; Santini G; Pozzato G
    Cancer; 1996 Jun; 77(12):2604-13. PubMed ID: 8640712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Large dose natural interferon alpha therapy for patients with chronic hepatitis C.
    Ohmiya M; Hayashi J; Furusyo N; Ueno K; Kishihara Y; Nabeshima S; Kashiwagi S
    Fukuoka Igaku Zasshi; 1997 Dec; 88(12):380-8. PubMed ID: 9465478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C.
    Karino Y; Toyota J; Sugawara M; Higashino K; Sato T; Ohmura T; Suga T; Okuuchi Y; Matsushima T
    Am J Gastroenterol; 1997 Jan; 92(1):61-5. PubMed ID: 8995939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma?
    Tanaka K; Sata M; Uchimura Y; Suzuki H; Tanikawa K
    Oncol Rep; 1998; 5(1):205-8. PubMed ID: 9458323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
    Ahmad J; Dodson SF; Demetris AJ; Fung JJ; Shakil AO
    Liver Transpl; 2001 Oct; 7(10):863-9. PubMed ID: 11679984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon.
    Mazzoran L; Grassi G; Giacca M; Gerini U; Baracetti S; Fanni-Canelles M; Zorat F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):338-42. PubMed ID: 9476188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The successful treatment of chronic active hepatitis due to hepatitis C viral infection with alpha-interferon and a cytokine complex (a clinical case)].
    Karpov VV; Krel' PE
    Ter Arkh; 1995; 67(5):84-5. PubMed ID: 7638792
    [No Abstract]   [Full Text] [Related]  

  • 30. [Treatment of chronic hepatitis C with IFN].
    Matsushima T
    Hokkaido Igaku Zasshi; 1993 Jul; 68(4):468-72. PubMed ID: 8393421
    [No Abstract]   [Full Text] [Related]  

  • 31. Lymphoblastoid interferon in patients with chronic nAnB hepatitis showing relapse during recombinant alpha interferon therapy.
    Mels GC; Roffi L; Antonelli G; Bellati G; Pacchetti S; Di Nolfo MA; Panizzuti F; Moretti G; Piperno A; Pozzi M
    Prog Clin Biol Res; 1993; 382():359-64. PubMed ID: 8502704
    [No Abstract]   [Full Text] [Related]  

  • 32. [Long-term prognosis after interferon therapy in chronic hepatitis type C].
    Inoue O; Yano M
    Nihon Rinsho; 1994 Jul; 52(7):1828-31. PubMed ID: 7521425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of viral hepatitis C: what are the perspectives?].
    Giostra E; Malè PJ
    Rev Med Suisse Romande; 1994 Sep; 114(9):759-64. PubMed ID: 7939106
    [No Abstract]   [Full Text] [Related]  

  • 34. [Interferon-alpha in chronic hepatitis C].
    Swobodnik W
    Dtsch Med Wochenschr; 1995 Aug; 120(34-35):1186. PubMed ID: 7656857
    [No Abstract]   [Full Text] [Related]  

  • 35. [When should the treatment with interferon alpha be discontinued in chronic hepatitis C?].
    Castilla Cortázar A
    Med Clin (Barc); 1993 Dec; 101(20):774-6. PubMed ID: 8114538
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of type C chronic active hepatitis with interferon-alpha 2a. Treatment duration does not influence biochemical remission but does decrease the relapse rate.
    Attili AF; Natali L; Onori L; Festuccia V; Natali GF
    J Clin Gastroenterol; 1994 Oct; 19(3):214-6. PubMed ID: 7806832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of interferon re-therapy and its adaptation in chronic hepatitis C].
    Matsuo S; Ohnishi K; Fujiwara K
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):1012-6. PubMed ID: 7563658
    [No Abstract]   [Full Text] [Related]  

  • 38. [Is the treatment of chronic viral hepatitis C with interferon-alpha effective?].
    Beker S; Pujol FH; Beker B
    G E N; 1995; 49(2):165-9. PubMed ID: 8566691
    [No Abstract]   [Full Text] [Related]  

  • 39. Canities and vitiligo complicating interferon therapy for hepatitis C.
    Bernstein D; Reddy KR; Jeffers L; Schiff E
    Am J Gastroenterol; 1995 Jul; 90(7):1176-7. PubMed ID: 7611226
    [No Abstract]   [Full Text] [Related]  

  • 40. [Interferon treatment for chronic hepatitis C--assessment of 3 regimens in patients received more than 500 MU interferon treatment and their effect predictive factors for interferon treatment using multivariate analysis with the logistic regression model].
    Terada M
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):1007-11. PubMed ID: 7563657
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.